New Combo Therapy Gives Myeloma Patients 80% 2-Year Win Rate

Patients with multiple myeloma just gained a powerful new weapon in their fight against this relentless blood cancer.

In a major international study involving more than 860 patients across 18 countries, a new immunotherapy combination helped 80% of participants live two years without their cancer progressing. That's a striking improvement over the 50% success rate seen with standard treatment.

Dr. Peter Voorhees from Wake Forest University School of Medicine presented the findings at the European Hematology Association Congress in Sweden. The results were simultaneously published in the New England Journal of Medicine.

The new treatment combines talquetamab, an innovative therapy that trains the body's own T cells to hunt down and destroy cancer cells, with existing medications. Multiple myeloma is a blood cancer that almost always returns after initial treatment, and each time it comes back, it becomes harder to control.

"When multiple myeloma comes back, it can be incredibly difficult for patients and their families," Voorhees said. "This study suggests we may be able to offer a treatment to give patients more time, better disease control and most importantly, renewed hope."

The trial tested two talquetamab combinations against the current standard therapy in patients whose cancer had returned after at least one previous treatment. Nearly nine out of ten patients receiving the new combinations saw their tumors shrink, compared with eight out of ten on standard care.

Even more encouraging, early data shows more patients in the talquetamab groups were alive at the two-year mark, though researchers need more time to confirm the full survival benefit.

The Bright Side

Side effects from the new treatment were manageable and expected based on the individual drugs involved. Some patients experienced taste changes, weight loss, or balance issues, but relatively few needed to stop treatment altogether.

The research team is already planning follow-up studies to track long-term survival and explore using these combinations earlier in the treatment journey, potentially helping patients before their cancer becomes harder to control.

For the thousands of people diagnosed with multiple myeloma each year, this breakthrough represents something precious: more time with loved ones and genuine reason for optimism.